Annual report
4078.TEDINET S100Q016
Period2020-04-01 → 2021-03-31
Filed2023-01-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amends S100LJGA.
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥84.9bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥87.2bn | 2019-04-01 → 2020-03-31 | Cons. | Net sales |
| Revenue | ¥89.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥87.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥83.9bn | 2016-04-01 → 2017-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.3bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Operating income | ¥4.0bn | 2019-04-01 → 2020-03-31 | Cons. | Operating income |
| Ordinary income | ¥4.0bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.2bn | 2019-04-01 → 2020-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.6bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2016-04-01 → 2017-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥2.0bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥4.0bn | 2019-04-01 → 2020-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥2.8bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.5bn | 2019-04-01 → 2020-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.3bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2016-04-01 → 2017-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥2.5bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Net income | ¥2.7bn | 2019-04-01 → 2020-03-31 | Cons. | Profit loss |
| Total assets | ¥123.0bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥121.6bn | at 2020-03-31 | Cons. | Assets |
| Total assets | ¥120.1bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥117.5bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥120.3bn | at 2017-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥43.7bn | at 2021-03-31 | Cons. | Liabilities |
| Total liabilities | ¥40.2bn | at 2020-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥79.3bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥81.5bn | at 2020-03-31 | Cons. | Net assets |
| Net assets / equity | ¥80.3bn | at 2019-03-31d | Cons. | Net assets |
| Net assets / equity | ¥80.8bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥81.9bn | at 2017-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥11.1bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.1bn | at 2020-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥11.2bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.1bn | at 2020-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.2bn | at 2019-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.8bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥14.6bn | at 2017-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥7.8bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.5bn | 2019-04-01 → 2020-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.9bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.7bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥8.4bn | 2019-04-01 → 2020-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥487m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.8bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.7bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥68m | 2019-04-01 → 2020-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥64m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-166.58 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥150.84 | 2019-04-01 → 2020-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥210.34 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥130.29 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥109.59 | 2016-04-01 → 2017-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,502.33 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,657.04 | at 2020-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,598.89 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,450.92 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,329.25 | at 2017-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 61.6% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.4% | at 2020-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.3% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.9% | at 2017-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | -3.6% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2019-04-01 → 2020-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.6% | 2016-04-01 → 2017-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,009 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 2,003 | at 2020-03-31 | Cons. | Number of employees |
| Employees | 1,964 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 1,875 | at 2018-03-31d | Cons. | Number of employees |
| Employees | 1,870 | at 2017-03-31d | Cons. | Number of employees |
| Revenue | ¥34.4bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥37.0bn | 2019-04-01 → 2020-03-31 | Standalone | Net sales |
| Revenue | ¥40.6bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥38.8bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥36.4bn | 2016-04-01 → 2017-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥105m | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Operating income | ¥419m | 2019-04-01 → 2020-03-31 | Standalone | Operating income |
| Ordinary income | ¥943m | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.0bn | 2019-04-01 → 2020-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.0bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.8bn | 2016-04-01 → 2017-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥5.0bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.8bn | 2019-04-01 → 2020-03-31 | Standalone | Income before income taxes |
| Net income | −¥4.1bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥1.6bn | 2019-04-01 → 2020-03-31 | Standalone | Profit loss |
| Net income | ¥2.0bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.3bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.7bn | 2016-04-01 → 2017-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥88.8bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥88.7bn | at 2020-03-31 | Standalone | Assets |
| Total assets | ¥84.6bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥81.7bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥82.8bn | at 2017-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥37.2bn | at 2021-03-31 | Standalone | Liabilities |
| Total liabilities | ¥33.3bn | at 2020-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥51.6bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥55.5bn | at 2020-03-31 | Standalone | Net assets |
| Net assets / equity | ¥55.3bn | at 2019-03-31d | Standalone | Net assets |
| Net assets / equity | ¥57.6bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥58.0bn | at 2017-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.2bn | at 2021-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.5bn | at 2020-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-245.57 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.38 | 2019-04-01 → 2020-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥114.76 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥183.6 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.25 | 2016-04-01 → 2017-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8 | 2016-04-01 → 2017-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,064.29 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,297.38 | at 2020-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,293.74 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,287.96 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,168.42 | at 2017-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 58.1% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.5% | at 2020-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.5% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.1% | at 2017-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -7.7% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2019-04-01 → 2020-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.9% | 2016-04-01 → 2017-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 17,000,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2020-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 20,987,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,939,000 | at 2017-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 774 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 776 | at 2020-03-31 | Standalone | Number of employees |
| Employees | 768 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 739 | at 2018-03-31d | Standalone | Number of employees |
| Employees | 719 | at 2017-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 57
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥107m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥141m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥16.4bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥1.9bn |
| Chemicalreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥9.5bn |
| Chemicalreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥3.9bn |
| Chemicalreportable segment | employees | at 2021-03-31 | 1669 pure |
| Chemicalreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥78.1bn |
| Chemicalreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥76.8bn |
| Chemicalreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥1.2bn |
| Chemicalreportable segment | segment assets | at 2021-03-31 | ¥93.1bn |
| Chemicalreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥5.7bn |
| Medicine And Healthcarereportable segment | capex | 2020-04-01 → 2021-03-31 | ¥982m |
| Medicine And Healthcarereportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥207m |
| Medicine And Healthcarereportable segment | employees | at 2021-03-31 | 271 pure |
| Medicine And Healthcarereportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥8.3bn |
| Medicine And Healthcarereportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥8.1bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥176m |
| Medicine And Healthcarereportable segment | segment assets | at 2021-03-31 | ¥13.6bn |
| Medicine And Healthcarereportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥452m |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥10.5bn |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥4.1bn |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥86.3bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥84.9bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥1.4bn |
| —segment total | segment assets | at 2021-03-31 | ¥106.6bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥6.2bn |
| Reconciling Itemsreconciling | capex | 2019-04-01 → 2020-03-31 | ¥80m |
| Reconciling Itemsreconciling | depreciation | 2019-04-01 → 2020-03-31 | ¥143m |
| Reconciling Itemsreconciling | revenue | 2019-04-01 → 2020-03-31 | −¥1.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2019-04-01 → 2020-03-31 | −¥1.6bn |
| Reconciling Itemsreconciling | segment assets | at 2020-03-31 | ¥11.9bn |
| Reconciling Itemsreconciling | segment profit | 2019-04-01 → 2020-03-31 | −¥2.2bn |
| Chemicalreportable segment | capex | 2019-04-01 → 2020-03-31 | ¥8.7bn |
| Chemicalreportable segment | depreciation | 2019-04-01 → 2020-03-31 | ¥3.3bn |
| Chemicalreportable segment | revenue | 2019-04-01 → 2020-03-31 | ¥79.9bn |
| Chemicalreportable segment | revenue external | 2019-04-01 → 2020-03-31 | ¥78.6bn |
| Chemicalreportable segment | revenue intersegment | 2019-04-01 → 2020-03-31 | ¥1.4bn |
| Chemicalreportable segment | segment assets | at 2020-03-31 | ¥95.9bn |
| Chemicalreportable segment | segment profit | 2019-04-01 → 2020-03-31 | ¥5.6bn |
| Medicine And Healthcarereportable segment | capex | 2019-04-01 → 2020-03-31 | ¥320m |
| Medicine And Healthcarereportable segment | depreciation | 2019-04-01 → 2020-03-31 | ¥199m |
| Medicine And Healthcarereportable segment | revenue | 2019-04-01 → 2020-03-31 | ¥8.8bn |
| Medicine And Healthcarereportable segment | revenue external | 2019-04-01 → 2020-03-31 | ¥8.6bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2019-04-01 → 2020-03-31 | ¥201m |
| Medicine And Healthcarereportable segment | segment assets | at 2020-03-31 | ¥13.9bn |
| Medicine And Healthcarereportable segment | segment profit | 2019-04-01 → 2020-03-31 | ¥594m |
| —segment total | capex | 2019-04-01 → 2020-03-31 | ¥9.1bn |
| —segment total | depreciation | 2019-04-01 → 2020-03-31 | ¥3.5bn |
| —segment total | revenue | 2019-04-01 → 2020-03-31 | ¥88.7bn |
| —segment total | revenue external | 2019-04-01 → 2020-03-31 | ¥87.2bn |
| —segment total | revenue intersegment | 2019-04-01 → 2020-03-31 | ¥1.6bn |
| —segment total | segment assets | at 2020-03-31 | ¥109.7bn |
| —segment total | segment profit | 2019-04-01 → 2020-03-31 | ¥6.2bn |
| Chemicalreportable segment | employees | at 2021-03-31 | 705 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,779
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 76821000000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 8096000000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReportableSegmentsMember | 84918000000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 84918000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 1243000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 176000000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReportableSegmentsMember | 1420000000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | -1420000000 | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 78065000000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 8272000000 | JPY |
| Net sales | CurrentYearDuration_ReportableSegmentsMember | 86338000000 | JPY |
| Net sales | CurrentYearDuration_ReconcilingItemsMember | -1420000000 | JPY |
| Net sales | CurrentYearDuration | 84918000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 5731000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 452000000 | JPY |
| Operating income | CurrentYearDuration_ReportableSegmentsMember | 6184000000 | JPY |
| Operating income | CurrentYearDuration_ReconcilingItemsMember | -1880000000 | JPY |
| Operating income | CurrentYearDuration | 4304000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 93081000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 13550000000 | JPY |
| Assets | CurrentYearInstant_ReportableSegmentsMember | 106631000000 | JPY |
| Assets | CurrentYearInstant_ReconcilingItemsMember | 16375000000 | JPY |
| Assets | CurrentYearInstant | 123007000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 3894000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 207000000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReportableSegmentsMember | 4102000000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReconcilingItemsMember | 141000000 | JPY |
| Depreciation segment information | CurrentYearDuration | 4243000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 9535000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 982000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_ReportableSegmentsMember | 10517000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_ReconcilingItemsMember | 107000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration | 10625000000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 18000000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | － | JPY |
| Impairment loss el | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Impairment loss el | Prior1YearDuration_UnallocatedAmountsAndEliminationMember | － | JPY |
| Impairment loss el | Prior1YearDuration | 18000000 | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 7002000000 | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 38000000 | JPY |
| Impairment loss el | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Impairment loss el | CurrentYearDuration_UnallocatedAmountsAndEliminationMember | － | JPY |
| Impairment loss el | CurrentYearDuration | 7041000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 135000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration_UnallocatedAmountsAndEliminationMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration | 135000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |